Program GoalsClick here to register for this event
This program is designed to improve clinical awareness of the fragile X syndrome (FXS) and in particular the role the causative gene FMR1 plays in premature ovarian failure. Historical and updated findings concerning the syndrome and FMR1 will be presented, along with requirements for accurate laboratory tests. Special emphasis is placed on the relationship between fragile X status (number of CGG repeats) and premature ovarian failure (POF), and strategy for prenatal genetic diagnosis.
Obstetricians/Gynecologists, Ph.D. Clinical Geneticists, M.D. Medical Geneticists, Genetic Counselors, Pediatricians, Nurses, Mental Health Specialists, Laboratory Professionals, and related healthcare professionals interested or involved in the clinical management of fragile X syndrome (FXS).
After completing this activity, the participant should be able to:
Joe Leigh Simpson, MD
Kenneth J. Friedman, PhD
05 minutes: Welcome & Introduction
Disclosure of Conflicts of Interests
Instructors, planners, managers and other individuals who are in a position to control the content of this activity are required to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.®accredited activity:
Planners and Managers
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Credit Designation - Lab Professional, P.A.C.E.®
The American Society for Clinical Laboratory Science's Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program will provide 1.5 contact hour of credit.
How to Obtain P.A.C.E.® Credit
ACCREDITATION FOR THIS ACTIVITY HAS EXPIRED
Viewers are expected to complete the presentation before attempting to submit contact information and the session evaluation. Successful completion will lead to the issuance of a certificate for 1.5 contact hour of P.A.C.E.® approved continuing education. To receive credit, the course must be completed by October 1, 2012.
Participation in this activity should be completed in approximately 1.5 hours. Please follow these steps in order to receive P.A.C.E.® credit for viewing the webcast:
Should you have any P.A.C.E.® questions regarding this activity, please contact:
Release and Expiration
Release Date: October 1, 2011
There is no fee for this educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Society for Clinical Laboratory Science (ASCLS) and Dane Garvin Ltd. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Policy on Privacy and Confidentiality
Dane Garvin Ltd. protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Dane Garvin Ltd. will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
Dane Garvin, Ltd. maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program has been made available online.
"Fragile X Syndrome: Premature Ovarian Failure and Molecular Diagnosis"
Commercial Support Statement
This activity supported by an educational grant from Abbott Molecular.
Copyright © October 1, 2011 - October 1, 2012 Dane Garvin, Ltd. All Rights Reserved. Permission for accreditation use granted to the American Society for Clinical Laboratory Science (ASCLS).